DGD Pharmaceuticals, Corp. is a team of passionate, committed, and experienced drug developers working to transform DGD1202, a first-in-class EGFR degrader, into a therapeutic reality.

  • Headquartered in Chicago, IL
  • Collaboration partnership with University of Michigan
  • A Subsidiary Company of MAIA Biotechnology, Inc.



To use cutting edge science to develop treatment options for patients resistant to currently available therapies.